HRP20190219T1 - Spojevi za tretman pretilosti i postupci za njihovu uporabu - Google Patents

Spojevi za tretman pretilosti i postupci za njihovu uporabu

Info

Publication number
HRP20190219T1
HRP20190219T1 HRP20190219TT HRP20190219T HRP20190219T1 HR P20190219 T1 HRP20190219 T1 HR P20190219T1 HR P20190219T T HRP20190219T T HR P20190219TT HR P20190219 T HRP20190219 T HR P20190219T HR P20190219 T1 HRP20190219 T1 HR P20190219T1
Authority
HR
Croatia
Prior art keywords
procedures
compounds
adult treatment
adult
treatment
Prior art date
Application number
HRP20190219TT
Other languages
English (en)
Croatian (hr)
Inventor
Umut Ozcan
Original Assignee
The Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children's Medical Center Corporation filed Critical The Children's Medical Center Corporation
Publication of HRP20190219T1 publication Critical patent/HRP20190219T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20190219TT 2013-11-26 2014-11-25 Spojevi za tretman pretilosti i postupci za njihovu uporabu HRP20190219T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908998P 2013-11-26 2013-11-26
EP14816018.7A EP3074033B1 (en) 2013-11-26 2014-11-25 Compounds for the treatment of obesity and methods of use thereof
PCT/US2014/067393 WO2015081093A1 (en) 2013-11-26 2014-11-25 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20190219T1 true HRP20190219T1 (hr) 2019-03-22

Family

ID=52134396

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190219TT HRP20190219T1 (hr) 2013-11-26 2014-11-25 Spojevi za tretman pretilosti i postupci za njihovu uporabu

Country Status (18)

Country Link
US (1) US20160375039A1 (enExample)
EP (1) EP3074033B1 (enExample)
JP (2) JP6672157B2 (enExample)
AU (2) AU2014354831B2 (enExample)
CA (1) CA2931826C (enExample)
CY (1) CY1122551T1 (enExample)
DK (1) DK3074033T3 (enExample)
ES (1) ES2709976T3 (enExample)
HR (1) HRP20190219T1 (enExample)
HU (1) HUE042196T2 (enExample)
LT (1) LT3074033T (enExample)
PL (1) PL3074033T3 (enExample)
PT (1) PT3074033T (enExample)
RS (1) RS58422B1 (enExample)
SI (1) SI3074033T1 (enExample)
SM (1) SMT201900064T1 (enExample)
TR (1) TR201901299T4 (enExample)
WO (1) WO2015081093A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN106008657B (zh) * 2016-05-20 2017-11-21 天津中医药大学 苦蘵苦素i及提取方法及用途
IT201800005336A1 (it) * 2018-05-14 2019-11-14 Composizioni per uso nel trattamento dell’obesità
US20210106525A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
CN113599502A (zh) * 2021-07-22 2021-11-05 廖儒佳 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
IL122718A0 (en) 1995-06-30 1998-08-16 Lilly Co Eli Methods for treating diabetes
ATE259650T1 (de) 1995-08-17 2004-03-15 Amgen Inc Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
CA2358862A1 (en) 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
WO1997048419A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Obタンパク質受容体をアップレギュレートすることによりobタンパク質に対する個体の感受性を増加させる方法
CA2266585A1 (en) 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
CA2275183A1 (en) 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
CN1202862C (zh) 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
JP2002504102A (ja) 1997-06-06 2002-02-05 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 糖尿病治療のためのレプチン拮抗物質の使用
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
JP4199421B2 (ja) 1998-08-10 2008-12-17 アムジエン・インコーポレーテツド デキストラン−レプチン結合体、医薬組成物および関連方法
EP1118001A1 (en) 1998-10-02 2001-07-25 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
ATE323766T1 (de) 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
JP2005506994A (ja) 2001-10-22 2005-03-10 アムジェン インコーポレイテッド ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
WO2007147883A1 (en) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US8598339B2 (en) * 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof

Also Published As

Publication number Publication date
AU2018200517A1 (en) 2018-02-15
JP6672157B2 (ja) 2020-03-25
RS58422B1 (sr) 2019-04-30
PT3074033T (pt) 2019-02-08
PL3074033T3 (pl) 2019-08-30
ES2709976T3 (es) 2019-04-22
CY1122551T1 (el) 2021-01-27
CA2931826C (en) 2021-11-16
AU2014354831B2 (en) 2017-10-26
AU2014354831A1 (en) 2016-06-09
SI3074033T1 (sl) 2019-03-29
HUE042196T2 (hu) 2019-06-28
JP2016537431A (ja) 2016-12-01
DK3074033T3 (en) 2019-02-11
WO2015081093A1 (en) 2015-06-04
LT3074033T (lt) 2019-02-25
SMT201900064T1 (it) 2019-02-28
EP3074033B1 (en) 2018-11-07
EP3074033A1 (en) 2016-10-05
TR201901299T4 (tr) 2019-02-21
CA2931826A1 (en) 2015-06-04
JP2020059744A (ja) 2020-04-16
US20160375039A1 (en) 2016-12-29
AU2018200517B2 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
IL268987B (en) System for glaucoma treatment
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
SI3033086T1 (sl) Kombinirana terapija za zdravljenje raka
DK2968208T3 (da) Behandling af kataplexi
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
HRP20182138T1 (hr) Modificirani serpini za liječenje poremećaja s krvarenjem
HRP20180478T1 (hr) Crenolanib za liječenje flt3 mutiranih proliferativnih poremećaja
LT3007726T (lt) Tautopatijos gydymo būdai
SI2991633T1 (sl) Terapija za bakteriofagi
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
HRP20181122T1 (hr) Postupak za pripremu jopamidola
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
HRP20181980T1 (hr) Ciklezonid za liječenje dišnih puteva kod konja
BR112016008387A2 (pt) Conjunto de absorvente descartável, e, artigo absorvente
EP2839068A4 (en) Clothes treatment apparatus
PL2948137T3 (pl) Sposoby leczenia zwłóknienia i nowotworów
EP2994184C0 (en) An unravelable catheter
DK2976101T3 (da) Behandlingsfremgangsmåde
DK3041506T3 (da) Behandlingsfremgangsmåde
HRP20181181T1 (hr) Postupak obrade i liječenja lišmenioze uporabom feksinidazola